Metformin (generic), Glucophage Wire
Comprehensive News Feed for Metformin (generic), Glucophage.
Results 1 - 20 of 486 in Metformin (generic), Glucophage
-
Roche, Ipsen note positive results in diabetes drug trial
PARIS An investigational diabetes drug developed by Roche and Ipsen offers glycemic control comparable to that of an insulin produced by Sanofi-Aventis, according to results of two late-stage clinical trials announced Thursday. Comment?
-
Roche, Ipsen note positive results in diabetes drug trial
PARIS An investigational diabetes drug developed by Roche and Ipsen offers glycemic control comparable to that of an insulin produced by Sanofi-Aventis, according to results of two late-stage clinical trials announced Thursday. Comment?
-
Ipsen's partner Roche announces that Taspoglutide meets its primary...
Ipsen , an innovationdriven global specialty pharmaceutical group, today announced that its partner Roche has disclosed headline results of the fourth and fifth of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first once weekly glucagon-like peptide-1 analogue based on a human sequence. Comment?
-
Roche, Ipsen Diabetes Drug Meets Goals in Studies
Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed headline results of the fourth and fifth of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first once weekly glucagon-like peptide-1 analogue based on a human sequence. Comment?
-
Ipsena s partner Roche announces that Taspoglutide meets its primary ...
Ipsen , an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed headline results of the fourth and fifth of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first once weekly glucagon-like peptide-1 analogue based on a human sequence. Comment?
-
Clinical Trials Update: Dec. 15, 2009
Depression This study seeks people diagnosed with depression that have not fully responded to an antidepressant medication. Comment?
-
Positive results from study comparing exenatide once weekly to BYETTA
Amylin Pharmaceuticals, Inc. , Eli Lilly and Company and Alkermes, Inc. today announced positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy, to BYETTAA injection taken twice daily, in patients with type 2 diabetes . Comment?
-
Santarus Announces Webcast Presentation at the Lippert/Heilshorn Life Sciences Virtual Conference
Santarus, Inc. announces the following webcast: Date: Tuesday, December 15, 2009 Time: 10:30 a.m. Eastern time Speaker: Gerald T. Proehl, Santarus president and chief executive officer The webcast can be accessed by visiting the Investor Relations section of the company's Web site at www.santarus.com . The webcast presentation will be archived and ... Comment?
-
Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.
RESEARCH DESIGN AND METHODS: This 28-week parallel-group study randomized 233 insulin-naive patients with HbA values>/=8.0% on>1,000 mg/day metformin alone or in combination with other OADs. Comment?
-
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
METHODS: In an open-label, controlled, multicenter trial, we randomly assigned 708 patients with a suboptimal glycated hemoglobin level who were receiving maximally tolerated doses of metformin and sulfonylurea to receive biphasic insulin aspart twice daily, prandial insulin aspart three times daily, or basal insulin detemir once daily . Comment?
-
Initial Therapy For Type 2 Diabetes
Healthcare providers can no longer use tradition or clinical experience alone to guide clinical care decisions. Comment?
-
A method of intensive diabetes self-management that involves keeping blood glucose levels as close as possible to normal without causing severe or frequent episodes of hypoglycemia , in the aim of preventing complications of diabetes. Comment?
-
New research shows one class of diabetes drugs may increase patients' risk of heart problems. Comment?
-
New Research Claims Diabetes Drug Has Higher Risk Of Heart Disease
Main Category: Diabetes Also Included In: Heart Disease ; Cardiovascular / Cardiology Article Date: 09 Dec 2009 - 19:00 PST New research claims that sulphonylureas, a class of drugs used to treat Type 2 diabetes , carry a greater risk of heart failure and death compared with the diabetes drug metformin. Comment?
-
Heart Disease And Diabetes: More Cutting Edge Science To Save Your Life
Few disease conditions are so thoroughly intertwined as coronary artery disease and diabetes. Comment?
-
What happened to the valid POEMs? A survey of review articles on the treatment of type 2 diabetes
Abstract Objective To evaluate systematically the review literature on type 2 diabetes to assess transmission of the findings of the United Kingdom prospective diabetes study , an important source of recent valid patient oriented evidence that matters . Comment?
-
More evidence that sulfonylureas are associated with increased mortality
This isn't new. In fact I've mentioned it here and in multiple other posts, but Internal Medicine News now reports : Four widely prescribed oral sulfonylurea drugs are associated with significantly increased risk of all-cause mortality compared with metformin in type 2 diabetic patients with a history of MI, according to a comprehensive Danish ... Comment?
-
Scientists Develop Rice To Treat Atopic Dermatitis, Diabetes
A group of South Korean scientists has developed a new type of rice, which could help to treat atopic dermatitis and diabetes, two diseases that afflicting countless people around the world, reported Yonhap news agency on Tuesday. Comment?
-
It is a devilish paradox: diabetes patients face an increased risk for heart disease and death due to their blood sugar problems, but the medications to treat the blood sugar disorder may raise heart risk even more . Comment?
-
Metformin vs. Sulfonylureas for Diabetes
Dec. 4, 2009 -- Concerns that the diabetes drugs Avandia and Actos raise the risk for heart failure led the FDA to require label changes warning of the potential risk two years ago. Comment?
Metformin (generic), Glucophage Forum
Most Popular
- San Francisco: The Worst-Run Big City in the U.S - 712 comments
- White Americans' majority to end by mid-century - 241 comments
- Bill would give undocumented legal status - 148 comments
- Obama Falters In Another Poll - 108 comments
- TV evangelist Oral Roberts dead at 91 - 117 comments
- Presiding over Senate, Franken declines to yield Lieberman additional time to... - 52 comments
- Arrests made in connection with Natchitoches homicide - 32 comments
- 'Santa' cited for open intoxicants - 59 comments
- Could Your Child Be Gay? What is and isn't known about kids' sexuality - 31 comments
- Former Sheriff Ancil Carter said he plans to file for office in January - 31 comments
|
Reach local customers. Engage a specific demographic. Maximize business-to-business opportunities. Topix can deliver your message.
|
Copyright ©2009 Topix LLC
